908 Devices Inc. (MASS)
NASDAQ: MASS · Real-Time Price · USD
5.37
-0.03 (-0.56%)
Apr 24, 2025, 2:17 PM EDT - Market open

Company Description

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets.

Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as process fingerprint data to support large-scale efforts in predictive bioprocess modeling.

The company’s products comprise Maven, an on-line device for bioprocess monitoring and control; Trace C2, an on-line monitoring of methanol or ethanol and control of substrate feeding in fermentation processes; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis.

It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas.

The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

908 Devices Inc.
908 Devices logo
Country United States
Founded 2012
IPO Date Dec 18, 2020
Industry Medical Devices
Sector Healthcare
Employees 246
CEO Kevin Knopp

Contact Details

Address:
645 Summer Street
Boston, Massachusetts 02210
United States
Phone 857 254 1500
Website 908devices.com

Stock Details

Ticker Symbol MASS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001555279
CUSIP Number 65443P102
ISIN Number US65443P1021
Employer ID 45-4524096
SIC Code 3829

Key Executives

Name Position
Dr. Kevin J. Knopp Ph.D. Co-Founder, Chief Executive Officer, President and Director
Joseph H. Griffith IV Chief Financial Officer and Treasurer
Michael S. Turner Esq., J.D. Chief Legal and Administrative Officer and Secretary
Dr. Christopher David Brown Ph.D. Co-Founder and Board Advisor
Barbara Russo Vice President of Marketing and Corporate Communications
Don Osmer Vice President of Human Resources

Latest SEC Filings

Date Type Title
Apr 7, 2025 SCHEDULE 13G Filing
Mar 7, 2025 8-K/A [Amend] Current report
Mar 7, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 7, 2025 10-K Annual Report
Mar 4, 2025 8-K Current Report
Mar 4, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Jan 30, 2025 SCHEDULE 13G/A Filing
Jan 10, 2025 SCHEDULE 13G/A Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals